Altor BioScience
Tracked across 3 events · 77 articles · First seen Apr 01, 2026 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Altor BioScience announced the initiation of the final stage of its PF614-MPAR-102 clinical study, which is a significant step in the development of its novel opioid overdose-protection technology. This could lead to a new standard for opioid safety and expand its market reach.
Jun 26, 2026 · 6 articles
Tech
Impact: Altor BioScience is leading the ROTOR project, developing an AI-powered platform for vaccine development, which enhances its R&D capabilities and global standing in the biotechnology sector.
Jul 02, 2026 · 7 articles
100
Altor BioScience initiated final stageEnsysce Biosciences...
100
Altor BioScience will leadSK bioscience leads Gates...
90
Altor BioScience will developSK bioscience leads Gates...
80
United States — Food and Drug Administration granted designation Altor BioScienceEnsysce Biosciences...
70
United States — National Institutes of Health supported study Altor BioScienceEnsysce Biosciences...
40
Altor BioScience entered license agreement United States — Centers for Disease Control and PreventionSK bioscience leads Gates...
30
Altor BioScience entered agreement Gates Medical Research InstituteSK bioscience leads Gates...
ERGEN INTELLIGENCE
Track Altor BioScience live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard